A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

April 17, 2025

Study Completion Date

April 17, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

ADCT-601

Intravenous (IV) infusion

DRUG

Gemcitabine

Intravenous (IV) infusion

Trial Locations (14)

28040

Hospital Universitario Fundacion Jimenez Diaz, Madrid

28050

Hospital Universitario Madrid Sanchinarro, Madrid

33076

Institut Bergonié, Bordeaux

37232

Vanderbilt University Medical Center (VUMC) - Ingram Cancer Center, Nashville

52242

University of IOWA, Iowa City

63110

Washington University School of Medicine, St Louis

69008

Institut Léon Bérard, Lyon

78229

Sarah Cannon at University of Oklahoma Health Sciences Center, Oklahoma City

90403

Sarcoma Oncology Research Center, Santa Monica

94305

Stanford Cancer Center, Stanford Medicine at Stanford University, Stanford

06189

Centre Antoine Lacassagne, Nice

08035

Hospital Universitario Vall d'Hebron, Barcelona

SW3 6JJ

The Royal Marsden NHS Foundation Trust, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

Sponsors
All Listed Sponsors
lead

ADC Therapeutics S.A.

INDUSTRY